These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 32782486)

  • 21. RAS/RAF mutations and their associations with epigenetic alterations for distinct pathways in Vietnamese colorectal cancer.
    Ta TV; Nguyen QN; Chu HH; Truong VL; Vuong LD
    Pathol Res Pract; 2020 Apr; 216(4):152898. PubMed ID: 32089414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.
    Grothey A; Fakih M; Tabernero J
    Ann Oncol; 2021 Aug; 32(8):959-967. PubMed ID: 33836264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.
    Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M
    Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
    Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
    Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular Targets for the Treatment of Metastatic Colorectal Cancer.
    Cohen R; Pudlarz T; Delattre JF; Colle R; André T
    Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32825275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular subtypes in early colorectal cancer associated with clinical features and patient prognosis.
    Gil-Raga M; Jantus-Lewintre E; Gallach S; Giner-Bosch V; Frangi-Caregnato A; Safont-Aguilera MJ; Garde-Noguera J; Zorraquino-Pina E; García-Martínez M; Camps-Herrero C
    Clin Transl Oncol; 2018 Nov; 20(11):1422-1429. PubMed ID: 29802524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.
    Custodio A; Feliu J
    Crit Rev Oncol Hematol; 2013 Jan; 85(1):45-81. PubMed ID: 22647972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review.
    Biller LH; Schrag D
    JAMA; 2021 Feb; 325(7):669-685. PubMed ID: 33591350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow.
    Pohl M; Schmiegel W
    Dig Dis; 2016; 34(5):574-9. PubMed ID: 27332557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.
    van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA
    J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ongoing and evolving clinical trials enhancing future colorectal cancer treatment strategies.
    Ros J; Saoudi N; Salvà F; Baraibar I; Alonso G; Tabernero J; Elez E
    Expert Opin Investig Drugs; 2022 Mar; 31(3):235-247. PubMed ID: 35133234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Developing Story of Predictive Biomarkers in Colorectal Cancer.
    Boussios S; Ozturk MA; Moschetta M; Karathanasi A; Zakynthinakis-Kyriakou N; Katsanos KH; Christodoulou DK; Pavlidis N
    J Pers Med; 2019 Feb; 9(1):. PubMed ID: 30736475
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted next generation sequencing of MLH1-deficient, MLH1 promoter hypermethylated, and BRAF/RAS-wild-type colorectal adenocarcinomas is effective in detecting tumors with actionable oncogenic gene fusions.
    Vaňková B; Vaněček T; Ptáková N; Hájková V; Dušek M; Michal M; Švajdler P; Daum O; Daumová M; Michal M; Mezencev R; Švajdler M
    Genes Chromosomes Cancer; 2020 Oct; 59(10):562-568. PubMed ID: 32427409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular targeted therapy for metastatic colorectal cancer: current and evolving approaches.
    Li F; Lin Y; Li R; Shen X; Xiang M; Xiong G; Zhang K; Xia T; Guo J; Miao Z; Liao Y; Zhang X; Xie L
    Front Pharmacol; 2023; 14():1165666. PubMed ID: 37927605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer - practical implications for the clinician.
    Afrăsânie VA; Marinca MV; Alexa-Stratulat T; Gafton B; Păduraru M; Adavidoaiei AM; Miron L; Rusu C
    Radiol Oncol; 2019 Sep; 53(3):265-274. PubMed ID: 31553708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Precision medicine for metastatic colorectal cancer: an evolving era.
    Guler I; Askan G; Klostergaard J; Sahin IH
    Expert Rev Gastroenterol Hepatol; 2019 Oct; 13(10):919-931. PubMed ID: 31475851
    [No Abstract]   [Full Text] [Related]  

  • 37. Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer.
    Sartore-Bianchi A; Siena S
    Handb Exp Pharmacol; 2018; 249():145-159. PubMed ID: 28382467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.
    Shen Y; Wang J; Han X; Yang H; Wang S; Lin D; Shi Y
    PLoS One; 2013; 8(12):e81628. PubMed ID: 24339949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer.
    Osumi H; Shinozaki E; Wakatsuki T; Suenaga M; Ichimura T; Ogura M; Takahari D; Ooki A; Suzuki T; Ota Y; Nakayama I; Chin K; Miki Y; Yamaguchi K
    Int J Cancer; 2019 Nov; 145(9):2488-2495. PubMed ID: 30963570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.